Journal
CLINICAL COLORECTAL CANCER
Volume 10, Issue 4, Pages 218-226Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clcc.2011.10.001
Keywords
Adjuvant chemotherapy; Bevacizumab; Biomarkers; Cetuximab; Elderly; Fluoropyrimidines; Oxaliplatin; Phase III; Stage II colon cancer; Stage III colon cancer
Categories
Funding
- Sanofi
- Roche
- Merck-Serono
Ask authors/readers for more resources
Adjuvant treatment of colon cancer, one of the most common malignancies, is an important issue in oncology. This article describes the development of adjuvant therapy and how the 2 major evolution steps, the successes of fluoropyrimidines, and then of oxaliplatin, have been achieved, Problems and failures, such as those of targeted therapies, also are addressed to help us to overcome their limitations. Special situations, such as stage II disease and an elderly population in which adjuvant chemotherapy is still controversial, are reviewed from the clinician perspective. The synthesis of these data allows us to conceive a future development focused on translational research. Clinical Colorectal Cancer, Vol. 10, No. 4, 218-26 (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available